Targeting AKT in HER2-Negative Breast Cancer: Implications for Future Clinical Practice

Review AKT as a therapeutic target in HER2-negative metastatic breast cancer and the potential of investigational AKT inhibitors in a focused text module, expert commentary, downloadable slideset, and infographic.

Share

Program Content

Activities

Targeting AKT in HER2-Negative BC
Targeting AKT in HER2-Negative Breast Cancer: Implications for Future Clinical Practice
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: July 27, 2023

Expires: July 26, 2024

Activities

Downloadable Slideset
Targeting AKT in HER2-Negative Breast Cancer: Implications for Future Clinical Practice
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 27, 2023

Activities

AKT Inhibitors in MBC
My Thoughts on the Potential of AKT Inhibitors in Metastatic Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 15, 2023

Activities

Targeting AKT in Breast Cancer
Targeting AKT in Breast Cancer: Emerging Therapies
Video
Congratulations: You achieved a completion on 04/09/2022

Released: September 22, 2023

Faculty

cover img faculity

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, Texas

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca